Venture funding for early-stage biotech companies has cooled significantly over the past year, forcing local startups to rethink timelines, headcount, and fundraising strategy. Founders and investors describe a market that rewards capital efficiency over rapid scaling, with several companies extending runway by narrowing their focus to a single lead program.
How Boston’s Biotech Startups Are Weathering the Funding Slowdown
Founders are stretching runway as venture capital cools
